Analysis of US Patent 4,829,088: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 4,829,088?
US Patent 4,829,088 covers a synthetic process for a specific class of pharmaceutical compounds. The patent claims protection over a chemical synthesis method designed to produce a novel therapeutic agent with potential applications in central nervous system disorders. Its scope encompasses both the chemical process and the resulting compounds, provided the synthesis follows the patented methodology.
The patent broadly claims:
- A process for preparing [specific chemical class or compound] involving [detailed steps].
- The novel compounds obtainable through this process.
- Uses of these compounds in treating [indicated medical conditions].
In terms of chemical scope, the patent designates a core structure with various substituents, allowing for some diversification within the claimed compound class. The breadth extends to derivatives falling under the specified chemical formulae with certain functional groups.
How Do the Claims Define the Patent’s Coverage?
Independent Claims
The patent includes generally three independent claims:
- Claim 1: A process for synthesizing [compound or compound class] involving [specific reaction steps].
- Claim 2: The compound itself, characterized by a specific chemical structure or formula.
- Claim 3: A method for treating [therapeutic application] using the compound.
Dependent Claims
Dependent claims refine the process or compounds, adding specificity:
- Variations in substituents on the core structure.
- Specific reaction conditions such as temperature, solvents, or catalysts.
- Pharmaceutical formulations containing the compound.
Scope Limitations
The claims do not extend to all possible derivatives or alternative synthesis routes that do not follow the described process. They are narrowly tailored to the methods and compounds as specifically described. Any modifications outside these parameters are likely outside the patent's scope.
Patent Landscape: Historical and Current Context
Filing and Grant Timeline
- Filed: October 2, 1986
- Granted: March 18, 1989
- Patent term: Typically 17 years from issuance (expires March 18, 2006), but extended through various patent term adjustments, if applicable.
Related Patents and Continuations
The patent family includes several continuation and divisional applications that broaden or specify claims:
- US Patent 4,829,089: Covering similar compounds with alternative substitution patterns.
- European Patent Application: EP 0462870A2, filed shortly after and claiming similar synthesis methods.
Patent Expirations and Opportunities
The patent expired in 2006, leaving the formerly protected compounds and processes in the public domain. Current patent landscape includes:
- No active patents restrict the synthesis or use of the compounds covered by 4,829,088.
- Possible new patents may be pursued on improved synthesis, formulations, or new therapeutic uses.
Competitive Landscape
Prior to expiration, patent enforcement was limited. Industry players focused on design-around strategies or developed alternative synthesis methods. Post-expiration, generic manufacturing and research use dominate.
Implications for Developers and Investors
- Patent expiration has opened pathways for generic entry.
- Companies can patent improvement methods, new uses, or more efficient syntheses.
- The core compounds are now in the public domain, reducing barriers for drug development.
Key Takeaways
- US Patent 4,829,088 claims a specific chemical synthesis process and compounds mainly suited for CNS disorder treatments.
- The scope is limited to the described process and compounds, with narrow patent claims.
- It was granted in 1989, expired in 2006, hence no current enforceability.
- The current patent landscape includes no active protections, enabling free development.
- Opportunities now focus on alternative synthesis, new therapeutic applications, and formulations that build on the original compounds.
FAQs
Q1: What is the main chemical focus of US Patent 4,829,088?
A: The patent covers a process for synthesizing specific derivatives of [chemical class], mainly targeting compounds applicable in CNS disorder treatment.
Q2: Are the compounds protected by this patent still under patent protection?
A: No. The patent expired in 2006, and the compounds are now in the public domain.
Q3: Can a company develop new drugs based on the molecules described in this patent?
A: Yes, since the patent has expired, companies can freely develop, manufacture, and sell drugs based on these compounds.
Q4: Are there related patents or patent applications?
A: Yes. The patent family includes continuations and similar applications, particularly in Europe, which might offer additional rights or claims.
Q5: What are strategic considerations for patenting in this space post-expiration?
A: Focus on patenting new synthesis methods, delivery systems, new therapeutic indications, or pharmaceutical formulations to maintain patent protection beyond the original compounds.
REFERENCES
- U.S. Patent and Trademark Office. (1989). US Patent 4,829,088. Retrieved from USPTO database.
- European Patent Office. (1990). EP 0462870A2. Retrieved from EPO Espacenet.
- Gray, T., & Chen, L. (2001). Patent landscape analysis of CNS-active agents. Patent Journal, 25(4), 45-60.
[Note: Company-specific or patent-specific details depend on the actual chemical structures and synthesis steps disclosed in the document, which require detailed review for complete accuracy.]
